EmbB 306 mutations as molecular indicators to predict ethambutol susceptibility in Mycobacterium tuberculosis

Chemotherapy

Volumn 58, Issue 5, 2013, Pages 358-363

  Sirgel, Frederick A ^a   Warren, Robin M ^a   Streicher, Elizabeth M ^a   Victor, Thomas C ^a   Van Helden, Paul D ^a   Böttger, Erik C ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antituberculosis drugs; Borderline resistance; Drug resistance; Mutations; Tuberculosis therapy

Indexed keywords

ETHAMBUTOL; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; DRUG SENSITIVITY; EMBB GENE; GENE; GENE MUTATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; ETHAMBUTOL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

MLCS; MLOWN;

EID: 84869227078     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000343474     Document Type: Article

References (25)

1. Sreevatsan S, Stockbauer KE, Pan X, Kreiswirth BN, Moghazeh SL, Jacobs WR Jr, Telenti A, Musser JM: Ethambutol resistance in Mycobacterium tuberculosis : critical role of embB mutations. Antimicrob Agents Chemother 1997; 41: 1677-1681.
2. Starks AM, Gumusboga A, Plikaytis B, Shinnick TM, Posey JE: Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis . Antimicrob Agents Chemother 2009; 53: 1061-1066.
3. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchok B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE: Molecular detection of mutations associated with firstand second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis . Antimicrob Agents Chemother 2011; 55: 2032-2041.
4. Plinke C, Walter K, Aly S, Ehlers S, Niemann S: Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo. Antimicrob Agents Chemother 2011; 55: 2891-2896.
5. Mokrousov I, Otten I, Vyshnevskiy B, Narvskaya O: Detection of embB mutations in ethambutol susceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotype resistance testing. J Clin Microbiol 2002; 40: 3810-3813.
6. Hazbón MH, Bobadilla del Valle M, Guerrero MI, Varma-Basil M, Filliol I, Cavatore M, Colangeli R, Safi H, Billman-Jacobe H, Lavender C, Fyfe J, García-García L, Davidow A, Brimacombe M, León CI, Porras T, Bose M, Chaves F, Eisenach KD, Sifuentes-Osornio J, Ponce de León A, Cave MD, Alland D: Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother 2005; 49: 3794-3802.
7. Böttger EC: Drug resistance in Mycobacterium tuberculosis : molecular mechanisms and laboratory susceptibility testing; in Donald PR, van Helden PD (eds): Progress in Respiratory Research: Antituberculosis Chemotherapy. Basel, Karger, 2011, vol 40, pp 128-144.
8. Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchock B, Sloutsky A, Washabaugh G, Mazurek G, Ridderhof J: Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 2002; 40: 3976-3979.
9. Ahmad S, Jaber AA, Mokaddas E: Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis 2007; 87: 123-129.
10. World Health Organization (WHO), Geneva, Switzerland: Policy guidance on drugsusceptibility testing (DST) of second line antituberculosis drugs. WHO/HTM/TB/2008.392:WHO, 2008, pp 1-20. http://www.who.int/tb/publications/2008/ whohtmtb-2008-392/en/index.html (accessed August 30, 2012).
11. Kremer K, van der Werf J, Au BKU, Anh DD, Kam KM, Rogier van Doorn H, Borgdorff MW, van Soolingen D: Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strains. Emerg Infect Dis 2009; 15: 335-339.
12. Streicher EM, Warren RM, Kewley C, Simpson J, Rastogi N, Sola C, van der Spuy GD, van Helden PD, Victor TC: Genotypic and phenotypic characterization of drug resistant Mycobacterium tuberculosis isolates from rural districts of the Western Cape Province of South Africa. J Clin Microbiol 2004; 42: 891-894.
13. Johnson R, Jordaan AM, Pretorius L, Engelke E, van der Spuy G, Kewley C, Bosman M, van Helden PD, Warren R, Victor TC: Ethambutol resistance by mutation detection. Int J Tuberc Lung Dis 2006; 10: 68-73.
14. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger EC: Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT960 and EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773-1780.
15. Pasipanodya JG, Gumbo T: A new evolutionary and pharmacokinetic pharmacodynamic scenario for rapid emergence of resistance to single and multiple antituberculosis drugs. Curr Opin Pharmacol 2011; 11: 457-463.
16. Donald PR, Maher D, Maritz JS, Qazi S: Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis 2006; 10: 1316-1330.
17. Safi H, Fleischmann RD, Peterson SN, Jones MB, Jarrahi B, Alland D: Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54: 103-108.
18. Ramaswamy S, Musser JM: Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis : 1998 update. Tuber Lung Dis 1998; 79: 3-29.
19. Goude R, Amin AG, Chatterjee D, Parish T: The arabinosyltransferase EmbC inhibited by ethambutol in Mycobacterium tuberculosis . Antimicrob Agents Chemother 2009; 53: 4138-4146.
20. Ramaswamy SV, Amin AG, Göksel S, Stager CE, Dou SJ, Sahly HEL, Moghazeh SL, Kreiswirth BN, Musser JM: Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 326-336.
21. Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, Rüsch-Gerdes S, Niemann S: Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC Microbiol 2012; 12: 90.
22. Plinke C, Cox HS, Zarkua N, Karimovich HA, Braker K, Diel R, Rüsch-Gerdes S, Feuerriegel S, Niemann S: embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB 306 mutation. J Antimicrob Chemother 2010; 65: 1359-1367.
23. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T: Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010; 201: 1225-1231.
24. Merza MA, Farnia P, Salih AM, Masjedi MR, Velayati AA: The most predominant spoligopatterns of Mycobacterium tuberculosis isolates among Iranian, Afghan-immigrant, Pakistani and Turkish tuberculosis patients: a comparative analysis. Chemotherapy 2010; 56: 248-257.
25. Fahimi F, Kobarfard F, Tabarsi P, Hemmati S, Salamzadeh J, Baniasadi S: Isoniazid blood levels in patients with pulmonary tuberculosis at a tuberculosis referral center. Chemotherapy 2011; 57: 7-11.